Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid

Emily E Hartung, Kanwaldeep Singh, Sarah Coopersmith, Jamie Avrumutsoae, Siddaarth Varatharajan, Sara Pishyar, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Ronan Foley, Brian Leber, Irwin Walker, Kylie L. Lepic, Maria Kleppe, Hugh Young Rienhoff, Jr., Tobias Berg

Blood (2024) 144 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2024-199648

Published: 2024

Journal Articles

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Irwin Walker, Uday Deotare, Mohamed Elemary, Mahmoud Elsawy, Genevieve Gallagher, David Kliman, Tony Panzarella, Nada Hamad, Kirk R. Schultz, Jan Storek, Kristjan Paulson

Blood (2024) 144 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2024-198798

Published: 2024

Journal Articles

Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant

Michael Radford, Alejandro Garcia-Horton, Rohail Badami, Elaine Jin, Nida Javed Usmani, Daria Grafodatskaya, Elizabeth McCready, Dina Khalaf, Irwin Walker, Brian Leber, Kylie L. Lepic, Gregory Pond, Tobias Berg

Blood (2023) 142 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2023-187458

Published: 2023

Journal Articles

Ureaplasma -Induced Hyperammonemia Syndrome - an Acute Complication Post Allogeneic Stem Cell Transplant

Rohail Badami, Kylie L. Lepic, Dina Khalaf, Alejandro Garcia-Horton, Tobias Berg, Brian Leber, Irwin Walker, Michael Radford

Blood (2023) 142 (Supplement 1): 6988.

https://doi.org/10.1182/blood-2023-182897

Published: 2023

Journal Articles

LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism

Kanwaldeep Singh, Emily Hartung, Christina Muhs, Islam Alshamleh, Monisha Divakaran, Anna Dvorkin-Gheva, Sara Pishyar, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Stephen Ronan Foley, Brian Leber, Irwin Walker, Kylie Lepic, Harald Schwalbe, Hubert Serve, Maria Kleppe, Hugh Young Rienhoff, Jr., Tobias Berg

Blood (2023) 142 (Supplement 1): 4156.

https://doi.org/10.1182/blood-2023-189515

Published: 2023

Journal Articles

LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses

Yu Yan, Kanwaldeep Singh, Emily Hartung, Brendan Lee, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Brian Leber, Irwin Walker, Kylie L. Lepic, Maria Kleppe, Hugh Young Young Rienhoff Jr., Jr., Jonathan Bramson, Tobias Berg

Blood (2023) 142 (Supplement 1): 6793.

https://doi.org/10.1182/blood-2023-188472

Published: 2023

Journal Articles

A Retrospective Cohort Study of Donor Cell Leukemia

Brittany Salter, Omar Raslan, Suzanne Demczuk, Brian Leber, Alejandro Garcia-Horton, Irwin Walker, Tobias Berg, Darci Butcher, Kylie L. Lepic, Elizabeth McCready, Parveen Wasi, Dina Khalaf

Blood (2022) 140 (Supplement 1): 12916–12917.

https://doi.org/10.1182/blood-2022-164643

Published: 2022

Journal Articles

Fitness Assessment of Elderly Patients with AML and Outcomes

Tony HT Chen, Joshua Xu, Hassan Zahreddine, Brian Leber, Irwin Walker, Tobias Berg, Kylie L. Lepic, Parveen Wasi, Tom Kouroukis, Christopher M. Hillis, Justin Y. Lee, Dina Khalaf

Blood (2021) 138 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2021-152612

Published: 2021

Journal Articles

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Denis Claude Roy, MD, Irwin Walker, MBBS, FRCPC, Johan A. Maertens, MD PhD, Philippe Lewalle, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva Maria Wagner, MD, Halvard Bönig, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 592.

https://doi.org/10.1182/blood-2019-128344

Published: 2019

Journal Articles

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Jean Roy, MD, Tony Panzarella, M.Sc., P.Stat, Stephen Couban, MDBSc, Félix Couture, MD FRCPC, Gerald M. Devins, PhD, Mohamed Elemary, MD, Stephen Ronan Foley, MD FRCPC, Genevieve Gallagher, MD, John Kuruvilla, MD, Stephanie J. Lee, MD MPH, John Moore, MDFRACP,FRCPA, Thomas J Nevill, MD, Gizelle Popradi, MD FRCP, Kirk R. Schultz, MD, David Szwajcer, MD FRCPC, Cynthia L Toze, MD FRCPC, Irwin Walker, MBBS, FRCPC

Blood (2019) 134 (Supplement_1): 875.

https://doi.org/10.1182/blood-2019-123275

Published: 2019

Journal Articles

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Denis-Claude Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD, Philippe Lewalle, MD, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva-Maria Wagner, MD, Halvard Bonig, MD, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2018) 132 (Supplement 1): 120.

https://doi.org/10.1182/blood-2018-99-119086

Published: 2018

Journal Articles

Provincial Disparities in Access to Allogeneic Transplant in Canada

Kristjan Paulson, MD, Oliver Bucher, Geoffrey Cuvelier, MD, Andrew Daly, MD, Alina S. Gerrie, MD MPH, David Sanford, MD, David Szwajcer, MD FRCP(C), Matthew Seftel, MRCP, MD MPH, FRCPC, Irwin Walker, MBBS, Natasha Kekre, MD FRCPC, Tony H Truong, MD FRCPC, Donna Wall, MD CCPE, Kirk R. Schultz, MD, Stephen Couban, MDBSc, Christopher Bredeson, MD FRCPC, MSc

Blood (2018) 132 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2018-99-113849

Published: 2018

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Jean-Sebastien Delisle, MD PhD, Stephen Ronan Foley, MD, Philippe Lewalle, MDPhD, Eduardo Olavarria, Dominik Selleslag, MD, Manfred Rüdiger, PhD, Jurjen Velthuis, PhD, Lisya Gerez, Jeroen Rovers, MD PhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2016) 128 (22): 1226.

https://doi.org/10.1182/blood.V128.22.1226.1226

Published: 2016

Journal Articles

Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation (TRIST Study): A Randomized Controlled Trial Evaluating 2 Red Cell Transfusion Thresholds

Jason Tay, MDFRCPC MSc, David S. Allan, MD FRCPC, Elizabeth Chatelain, Doug Coyle, Mohamed Elemary, MD MSc,PhD, William Petrcich, Timothy Ramsay, Alan Tinmouth, MD FRCPC, Irwin Walker, MBBS, Anargyros Xenocostas, MD, Dean Fergusson, MHA, PhD

Blood (2016) 128 (22): 1032.

https://doi.org/10.1182/blood.V128.22.1032.1032

Published: 2016

Journal Articles

Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure

Dennis Dong Hwan Kim, MD PhD, Mary Lynn Savoie, MD, Isabelle Bence-Bruckler, MD FRCPC, Lothar B. Huebsch, MD, Marc Lalancette, MDFRCP-C, Christopher M. Hillis, MD FRCPC, Irwin Walker, MBBS, Donna L. Forrest, MD, Jeff H. Lipton, MD PhD

Blood (2016) 128 (22): 1907.

https://doi.org/10.1182/blood.V128.22.1907.1907

Published: 2016

Journal Articles

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3 + NK cells

Blood (2016) 127 (24): 3082–3091.

https://doi.org/10.1182/blood-2015-09-668251

Published: 2016

Includes: Supplemental data

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Sandra Cohen, MD, Stephen Ronan Foley, MD, Philippe Lewalle, MD PhD, Eduardo Olavarria, MD PhD, Dominik Selleslag, MD, Manfred Rudiger, Jurjen Velthuis, PhD, Karen Reitsma, PhD, Lisya Gerez, Jeroen Rovers, MDPhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2015) 126 (23): 4391.

https://doi.org/10.1182/blood.V126.23.4391.4391

Published: 2015

Journal Articles

Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure

Dennis Dong Hwan Kim, MDPhD, Isabelle Bence-Bruckler, MD FRCPC, Christopher M. Hillis, MD FRCPC, Irwin Walker, MBBS, Suzanne Kamel-Reid, PhD, Jeffrey H. Lipton, MD PhD

Blood (2014) 124 (21): 4554.

https://doi.org/10.1182/blood.V124.21.4554.4554

Published: 2014

Journal Articles

Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS

Denis-Claude Roy, MD, Johan Maertens, MD PhD, Irwin Walker, MBBS, Silvy Lachance, MD, Jean Roy, MD, Stephen Ronan Foley, MD, Philippe Lewalle, MD PhD, Dominik L.D. Selleslag, MD, Liesbeth De Jong, PhD, Jurjen H.L. Velthuis, PhD, Lisya Gerez, PhD, Karen Reitsma, PhD, Edwin Wagena, PhD, Stephan Mielke, MD

Blood (2014) 124 (21): 314.

https://doi.org/10.1182/blood.V124.21.314.314

Published: 2014

Journal Articles

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Irwin Walker, MBBS, Kirk R. Schultz, MD, Cynthia L. Toze, MD FRCPC, Holly Margaret Kerr, RN, BSN, John Moore, MD, David Szwajcer, MD FRCPC, Stephen Ronan Foley, MD FRCPC, John Kuruvilla, MD FRCPC, Tony Panzarella, M.Sc, Félix Couture, MD, Jean Roy, MD, Stephen Couban, MD FRCPC, Gerald Devins, PhD, Gizelle Popradi, FRCPC, MD, Stephanie J. Lee, MD MPH, Jason Tay, MD MSc, FRCPC, Thomas J. Nevill, MD FRCPC, Mohamed Elemary, MD MSc,PhD, Genevieve Gallagher, MD FRCPC

Blood (2014) 124 (21): 38.

https://doi.org/10.1182/blood.V124.21.38.38

Published: 2014

NARROW

The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant

Ureaplasma -Induced Hyperammonemia Syndrome - an Acute Complication Post Allogeneic Stem Cell Transplant

LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism

LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses

A Retrospective Cohort Study of Donor Cell Leukemia

Fitness Assessment of Elderly Patients with AML and Outcomes

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Provincial Disparities in Access to Allogeneic Transplant in Canada

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation (TRIST Study): A Randomized Controlled Trial Evaluating 2 Red Cell Transfusion Thresholds

Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3 + NK cells

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure

Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only